CellsBin Secures Series A Financing to Advance Rare-Cell Intelligence Platform
News related to:CellsBin · 2 min read
BRANFORD, Conn., Sept. 22, 2026 /CourierPR/ -- CellsBin, a biotechnology company pioneering Rare-Cell Biology, has secured a significant Series A financing round, led by 108 BioCapital. The investment will accelerate the company's commercialization efforts, strategic partnerships, and product development, as well as bolster its clinical and technical capabilities.
Founded on the premise of integrating advanced microfluidics, multimodal imaging, single-cell analysis, and artificial intelligence, CellsBin's Rare-Cell Intelligence Platform aims to make rare cells visible, measurable, and actionable. The platform is designed to reveal biological signals that are often missed by conventional methods, providing researchers and clinicians with deeper insights into therapeutic cell behavior, disease progression, and patient responses to cell therapy.
The company's platform combines several key technologies: - Ultrasensitive Rare-Cell Detection: Enabling the detection of extremely rare cells. - High-Dimensional Cellular Profiling: Offering detailed analysis of cellular characteristics. - Longitudinal Biological Monitoring: Tracking biological changes over time. - Proprietary Datasets and AI-Driven Analysis: Providing robust, data-driven insights.
CellsBin's initial applications focus on cell and gene therapy monitoring and hematologic cancers, with the broader goal of establishing Rare-Cell Biology as a foundational discipline across research, drug development, and clinical medicine. The company's vision is to enable smarter decisions, earlier care, and better patient outcomes through its innovative platform.
The company plans to use the funds to accelerate commercial adoption, expand strategic and channel partnerships, advance its research and product-development roadmap, strengthen its clinical evidence base, and grow its commercial, scientific, and technical teams.
CellsBin's platform is designed to integrate seamlessly with existing workflows, providing a new layer of precision in medical diagnostics and therapeutic monitoring. The company's approach is expected to revolutionize the way rare cells are studied and managed, potentially leading to breakthroughs in personalized medicine and improved patient care. The Rare-Cell Intelligence Platform is expected to help researchers and clinicians understand how therapeutic cells behave, how diseases evolve, and why patients respond differently to cell therapy.
The investment will support CellsBin's efforts to expand its network of strategic, clinical, and commercial relationships, deepen its market and channel reach, and build the necessary capabilities to establish Rare-Cell Biology as a foundational discipline. The company's goal is to make rare cells visible, measurable, and actionable, thereby enabling smarter decisions, earlier care, and better patient outcomes.
This financing represents a significant step forward for CellsBin and its commitment to advancing the field of Rare-Cell Biology. The company's platform is expected to have a profound impact on precision medicine, providing new tools and insights for researchers and clinicians to better understand and manage rare cells.